Spyre Therapeutics, Inc.
SYRENASDAQHealthcare● Active
$72.00
$-1.65(-2.24%)
Market Cap$4.3B
P/E Ratio—
52W High$78.8
52W Low$13.93
Spyre Therapeutics, Inc. (SYRE) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · SYRE · as of 2026-06-08
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $0.00B | $0.00B | $0.00B | $0.00B | $0.02B |
| Cost of Revenue | $0.17B | $0.00B | $0.00B | $0.00B | $0.00B |
| Gross Profit | ($0.17B) | $0.00B | $0.00B | $0.00B | $0.02B |
| Gross Margin %(computed) | — | — | 100.00% | 100.00% | 100.00% |
| Operating Expenses | |||||
| R&D Expenses | $0.17B | $0.16B | $0.09B | $0.06B | $0.06B |
| G&A Expenses | $0.05B | $0.05B | $0.04B | $0.03B | $0.03B |
| Total Operating Expenses | $0.04B | $0.21B | $0.24B | $0.09B | $0.08B |
| Operating Income | ($0.21B) | ($0.21B) | ($0.24B) | ($0.08B) | ($0.07B) |
| Operating Margin %(computed) | — | — | — | — | -350.33% |
| Interest Income | $0.02B | $0.02B | $0.01B | $0.00B | $0.00B |
| Interest Expense | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Income Before Tax | ($0.16B) | ($0.21B) | ($0.34B) | ($0.08B) | ($0.07B) |
| Income Tax Expense | ($0.00B) | $0.00B | ($0.00B) | ($0.00B) | $0.00B |
| Net Income | ($0.16B) | ($0.21B) | ($0.34B) | ($0.08B) | ($0.07B) |
| Net Margin %(computed) | — | — | — | — | -351.14% |
| Per Share & EBITDA | |||||
| EPS (Basic) | $-1.98 | $-3.18 | $-46.15 | $-24.86 | $-25.02 |
| Wtd Avg Shares | 0.35B | 0.05B | 0.01B | 0.00B | 0.00B |
| EBITDA | ($0.21B) | ($0.21B) | ($0.13B) | ($0.08B) | ($0.06B) |
| EBITDA Margin %(computed) | — | — | — | — | -341.92% |
Data source: Financial Modeling Prep · Last updated: 2026-06-08 · USD · B
Explore more Spyre Therapeutics, Inc. data
About Spyre Therapeutics, Inc. (SYRE) Income Statement
Spyre Therapeutics, Inc. (SYRE) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2025, SYRE reported revenue of $0.00B, gross profit of ($0.17B) (gross margin —), and net income of ($0.16B) — a net profit margin of —.
Frequently asked questions
SYRE · 4 questionsSpyre Therapeutics, Inc. (SYRE) reported revenue of $0.00B for 2025, down —% year-over-year.
SYRE revenueSYRE salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-08